Nanosponges encapsulating dexamethasone for ocular delivery: Formulation design, physicochemical characterization, safety and corneal permeability assessment

Journal of Biomedical Nanotechnology

Volumn 9, Issue 6, 2013, Pages 998-1007

  Swaminathan, Shankar ^a,b,c   Vavia, Pradeep R ^a   Trotta, Francesco ^b   Cavalli, Roberta ^b  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Corneal permeability; Dexamethasone; Nanosponges; Ocular drug delivery

Indexed keywords

DEXAMETHASONES; ENCAPSULATION EFFICIENCY; FOURIER TRANSFORM INFRA REDS; NANOSPONGES; OCULAR DRUG DELIVERY; PHYSICO-CHEMICAL CHARACTERIZATION; POLYDISPERSITY INDICES; REFLECTANCE SPECTROSCOPY;

ATOMIC FORCE MICROSCOPY; CYCLODEXTRINS; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY; ENCAPSULATION; MAMMALS; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

POLYMER BLENDS;

BETA CYCLODEXTRIN; DEXAMETHASONE;

ARTICLE; ATOMIC FORCE MICROSCOPY; CORNEA PERMEABILITY; CROSS LINKING; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; ENCAPSULATION; EX VIVO STUDY; IN VITRO STUDY; PHYSICAL CHEMISTRY; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

ABSORPTION; ADMINISTRATION, OPHTHALMIC; ANIMALS; CATTLE; CORNEA; DEXAMETHASONE; DIFFUSION; MOLECULAR WEIGHT; NANOCAPSULES; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; PERMEABILITY; POROSITY; SURFACE PROPERTIES;

EID: 84877810618     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1594     Document Type: Article

References (38)

1. F. Trotta and W. Tumiatti, WO 03/085002 (2003).
2. S. Swaminathan, Studies on novel dosage forms. Masters of Pharmaceutical Sciences Dissertation submitted to the University of Mumbai, India (2006).
3. F. Trotta and R. Cavalli, Characterization and applications of new hyper-cross-linked cyclodextrins. Composite Interfaces 16, 39 (2009).
4. S. Swaminathan, Design and characterization of novel polymeric drug delivery system. Ph.D. (Tech.) Dissertation submitted to the University of Mumbai, India (2010).
5. R. Cavalli, F. Trotta, and W. Tumiatti, Cyclodextrin-based nanosponges for drug delivery. Journal of Inclusion Phenomenon and Macrocyclic Chemistry 56, 209 (2006).
6. S. Swaminathan, P. R. Vavia, F. Trotta, and S. J. Torne, Formulation of betacyclodextrin based nanosponges of itraconazole. Journal of Inclusion Phenomenon and Macrocyclic Chemistry 57, 89 (2007).
7. S. Swaminathan, P. R. Vavia, F. Trotta, R. Cavalli, L. Serpe, and G. P. Zara, Novel functionalized beta cyclodextrin nanosponge based stable formulation of camptothecin and In vitro cytotoxicity evaluation. A Poster Presented at the Fifth Asian Cyclodextrin Conference in Busan, Korea (2009).
8. S. Swaminathan, L. Pastero, L. Serpe, F. Trotta, P. R. Vavia, D. Aquilano, M. Trotta, G. P. Zara, and R. Cavalli, Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. European Journal of Pharmaceutics and Biopharmaceutics 74, 193 (2010).
9. S. Swaminathan, P. R. Vavia, R. Cavalli, F Trotta, P. Ferruti, E. Ranucci, I. Gerges, and A. Manfredi, In vitro release modulation and conformational stabilization of a model protein using swellable polyamidoamine nanosponges of β-cylcodextrin. Journal of Inclusion Phenomenon and Macrocyclic Chemistry 68, 183 (2010).
10. S. J. Torne, K. A. Ansari, P. R. Vavia, F Trotta, and R. Cavalli, Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Delivery 17, 419 (2010).
11. K. A. Ansari, S. J. Torne, P. R. Vavia, F Trotta, and R. Cavalli, Paclitaxel loaded nanosponges: In-vitro characterization and cytotoxicity study on MCF-7 Cell line Culture. Current Drug Delivery 8, 194 (2011).
12. K. A. Ansari, P. R. Vavia, F Trotta, and R. Cavalli, Cyclodextrin-based Nanosponges for Delivery of Resveratrol: In vitro characterization, stability, cytotoxicity and permeation study. AAPS Pharmsci tech 12, 279 (2010).
13. P. R. Vavia, S. Swaminathan, F Trotta, and R. Cavalli, Applications of nanosponges in drug delivery, XIII International Cyclodextrin Symposium, Turin (2006).
14. S. M. Agnihotri and P. R. Vavia, Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application, Nanomedicine: Nanotechnology, Biology and Medicine 5, 90 (2009).
15. A. Zimmer, H. Serbe, and J. Kreuter, Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye I. In vitro and in vivo characterization. J. Control Release 32, 57 (1994).
16. V. H. Li, R. W. Wood, J. Kreuter, T. Harmia, and J. R. Robinson, Ocular drug delivery of progesterone using nanoparticles. J. Microencapsul. 3, 13 (1986).
17. L. Marchal-Heussler, D. Sirbat, M. Hoffman, and P. Maincent, Poly(ε-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm. Res. 10, 386 (1993).
18. J. Kim and A. Chauhan, Dexamethasone transport and ocular delivery from poly(hydroxyethyl methacrylate) gels. International Journal of Pharmaceutics 353, 205 (2008).
19. A. F Clark and T. Yorio, Ophthalmic drug discovery. Nature Review Drug Discovery 2, 448 (2003).
20. J. C. Melby, Drug spotlight program: Systemic corticosteroid therapy: Pharmacology and endocrinologic considerations. Annals of Internal Medicine 81, 505 (1974).
21. B. Schwartz, The response of ocular pressure to corticosteroids. International Ophthalmology Clinics 6, 929 (1966).
22. R. C. Urban and E. Cotlier, Corticosteroid-induced cataracts. Survey of Ophthalmology 31, 102 (1986).
23. C. C. Li and A. Chauhan, Modeling ophthalmic drug delivery by soaked contact lenses. Industrial and Engineering Chemistry Research 45, 3718 (2006).
24. P. Ferrante, A. Ramsey, C. Bunce, and S. Lightman, Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clinical and Experimental Ophthalmology 32, 563 (2004).
25. S. Young, G. Larkin, M. Branley, and S. Lightman, Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clinical and Experimental Ophthalmology 29, 2 (2001).
26. H. W Kwak and D. J., D'Amico, Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Archives of Ophthalmology 110, 259 (1992).
27. P. Jansook, G. C. Ritthidej, H. Ueda, E. Stefánsson, and T. Loftsson, γCD/HPγCD Mixtures as solubilizer: Solid-state characterization and sample dexamethasone eye drop suspension. J. Pharm. Pharmaceut Sci. 13, 336 (2010).
28. J. K. Kristinsson, H. Fridriksddttir, S. Thorisdottir, A. M. Sigurdardottir, E. Stefansson, and T. Loftsson Dexamethasone-Cyclodextrin- Polymer Co-complexes in Aqueous Eye Drops Aqueous Humor Pharmacokinetics in Humans. Invest Ophthalmol. Vis Sci. 37, 1199 (1996).
29. E. Stefánsson and T. Loftsson, Cyclodextrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye. Acta ophthalmologica Scandinavica 80, 144 (2002).
30. S. J. Torne, Studies on novel dosage form. Ph.D. (Tech.) Dissertation submitted to the University of Mumbai, India (2007).
31. S. Swaminathan, P. R. Vavia, F Trotta, R. Cavalli, S. Tumbiolo, L. Bertinetti, and S. Coluccia, Structural evidence of differential forms of nanosponges of betacyclodextrin and its effect on solubilization of a model drug. Journal of Inclusion Phenomenon and Macrocyclic Chemistry (2012), Doi: 10.1007/s10847-012-0192-y.
32. S. Swaminathan and M. M. Jablonski, Non-biological membranes as drug delivery systems. J. Membra Sci. Technol. (2012), Doi: 10.4172/2155 9589.1000e108.
33. F. Trotta, Cyclodextrin nanosponges and their applications, In Cyclodextrins in Pharmaceutics, Cosmetics and Biomedicine, Current and Future Industrial applications, Ed. Erem Bilensoy (Wiley Publishers) (2011), pp. 323-342
34. S. S. Darandale and P. R. Vavia, Cyclodextrin-based nanosponges of curcumin: Formulation and physicochemical characterization. Journal of Inclusion Phenomenon and Macrocyclic Chemistry (2012), Doi: 10.1007/s10847-012-0186-9.
35. S. Swaminathan, S. S. Darandale, and P. R. Vavia, Nanosponge-Aided Drug Delivery: A Closer Look, Pharmaceutical Formulation and Quality, Drug delivery/bioavailability section, October/November (2012).
36. A. R. Hariri, E. M. Drabant, K. E. Munoz, B. S. Kolachana, V. S. Mattay, M. F. Egan, and D. R. Weinberger, A Susceptibility Gene for Affective Disorders and the Response of the Human Amygdala. Arch. Gen. Psychiatry 62, p. 146 (2005).
37. T. J. Cleophas and A. H. Zwinderman, Variability analysis with the Bartlett's test, Statistical analysis of clinical data on a pocket calculator, Part 2, Springer briefs in statistics, chapter 15, p. 55 (2012), Doi: 10.1007/978-94-007-4704-3-15.
38. M. Marusteri1 and V. Bacarea, Comparing groups for statistical differences: how to choose the right statistical test? Biochemia Medica; 20, 15 (2010).